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Abstract
The protozoan diseases leishmaniasis, Chagas’ disease and African trypanosomiasis are major health problems in many countries,
particularly developing countries, and there are few drugs available to treat these diseases. Dihydrofolate reductase (DHFR) inhibitors have
been used successfully in the treatment of a number of other diseases such as cancer, malaria and bacterial infections; however they have not
been used for the treatment of these diseases. This article summarises studies on leishmanial and trypanosomal DHFR inhibitor development
and evaluation. Possible mechanisms of resistance to DHFR inhibitors are also discussed. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Leishmaniasis, African trypanosomiasis (sleeping sick-
ness) and Chagas’ disease are major causes of mortality and
cause much economic hardship, particularly in the develop-
ing world. The World Health Organisation estimates that
millions of people are infected, or are at risk, from these
diseases [1]. In addition, leishmaniasis is increasingly a
complication with AIDS patients. Unfortunately, there are
few drugs available to treat these diseases and most of these
suffer from poor clinical efficacy, unwanted effects, and
require parenteral administration, which is not appropriate in
rural areas. The situation is made more serious by reports of
treatment failures of the existing drugs, for example, mel-
arsoprol for the treatment of African trypanosomiasis.
Dihydrofolate reductase (DHFR) is a key enzyme in folate
metabolism and, therefore, in the production of thymidine
[2,3]. Its role in thymidine biosynthesis is the reduction of
dihydrofolate to tetrahydrofolate using the cofactor NADPH
(Fig. 1). Following this reduction, tetrahydrofolate is meth-
enylated to form methylene-tetrahydrofolate, which then
methylates deoxyuridine monophosphate (dUMP) to give
TMP in a reaction catalysed by thymidylate synthase (TS)
(Fig. 1). During this reaction, methylene-tetrahydrofolate is
converted back to dihydrofolate, completing the cycle. There-
fore, inhibition of DHFR prevents biosynthesis of thymidine,
and as a consequence, DNA biosynthesis. In addition, inhib-
ition of DHFR probably leads to a buildup in levels of dUMP
and hence to a biosynthetic precursor, deoxyuridine triphos-
phate [4]. High levels of deoxyuridine triphosphate lead to
incorporation of uracil into DNA to levels beyond which the
DNA repair enzymes (uracil-DNA-glycosylase) can cope,
leading to cell death.
2. Background to the diseases
The parasites that cause leishmaniasis, African trypano-
somiasis and Chagas’ disease are protozoan parasites of the
order kinetoplastida [5,6]. They are all transmitted to the
human host by various vectors (see below) and have
complex life cycles; each stage of which has different
morphologies and different metabolic properties. The para-
sites are phylogenetically related and share many similar-
ities, but there are also significant differences between them.
Leishmaniasis is caused by various species and subspe-
cies of Leishmania, of which the most important include
subspecies of Leishmania donovani, Leishmania tropica,
Leishmania mexicana and Leishmania braziliensis. These
cause a variety of diseases in humans. The diseases found
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are: cutaneous leishmaniasis, which can vary from small
self-healing skin lesions to a more widespread and disfigur-
ing condition; mucocutaneous leishmaniasis, which leads to
highly disfiguring lesions of the mouth, nose and throat; and
visceral leishmaniasis, which is a systemic infection that is
usually fatal if not treated, with the parasites multiplying
within macrophages, giving rise to damage of the liver,
spleen, bone marrow and lymph nodes. The parasite is
found in the vector stage (the sandfly) as the promastigote
and in the human host as an amastigote in acidic phagoly-
somes within macrophages.
African trypanosomiasis in humans is caused by two
subspecies of Trypanosoma brucei: T. b. rhodesiense and T.
b. gambiense. The parasites live in the bloodstream and
invade the central nervous system giving rise to the neuro-
logical symptoms of African trypanosomiasis and eventu-
ally to death unless the disease is treated. The human form
of the life cycle is the trypomastigote and the vector stage
(tsetse fly) is the epimastigote.
Chagas’ disease is caused by the parasite Trypanosoma
cruzi. The parasite is found in the vector (reduviid bug) as
an epimastigote and in the human host as an intracellular
amastigote. The disease causes a chronic infection in
humans, with particular effects on the heart, colon, oeso-
phagus and peripheral nervous system. There is a high death
rate amongst children.
3. The parasite enzyme
3.1. Characterisation
DHFR has been cloned and over-expressed from Leish-
mania major, [7,8] T. cruzi [9] and T. brucei [10]. These
enzymes show high sequence identity, especially the T.
brucei and T. cruzi enzymes (Table 1). The enzyme is actually
a bi-functional dimeric enzyme linked to TS (Fig. 2). This is a
common occurrence amongst protozoa, in contrast to the
situation in mammalian and bacterial cells where the enzyme
is a monomer [11]. Gene knockout experiments have shown
the enzyme to be essential in Leishmania, at least in the
promastigote stage of the life cycle [12].
Fig. 1. The reaction carried out by DHFR: the reduction of dihydrofolate to tetrahydrofolate (shown in the box); and the role of this reaction in the folate-
mediated production of TMP from dUMP.
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3.2. Structural data
The enzyme from L. major has been crystallised by
Knighton et al. [13] and homology models have been
produced of the T. brucei and T. cruzi enzymes [14].
Detailed analysis [14] and comparison of the structures of
the L. major, human and bacterial enzymes, and the homol-
ogy models of the T. brucei and T. cruzi enzymes, suggests
the following:
. The L. major, T. brucei and T. cruzi enzymes show high
structural similarity.
. The three protozoan enzymes show structural differ-
ences from the human and bacterial enzymes.
. The three-dimensional shapes of the parasite enzyme
folate binding sites are slightly different to the correspond-
ing human active sites. Points of particular difference are: a
slightly larger binding pocket in the region where the
benzamide moiety of the substrate binds in the case of the
trypanosomal and leishmanial enzymes; and a small tunnel
under the pteridine ring in the case of the trypanosomal
enzymes.
. Differences in residues in the active sites (Table 2, Fig.
3).
It may be possible to exploit these differences between the
parasite and human enzymes to design selective inhibitors.
Knighton et al. [13] studied the crystal structure of the bi-
functional DHFR-TS enzyme and concluded that there is
substrate channelling between the DHFR and TS domains of
the enzyme, by a positively charged electrostatic channel on
the protein surface, which interacts with the negatively
charged substrate. Liang and Anderson [15] have done
detailed kinetic analysis, which supports this model and,
in addition, they suggest that there may be interaction
between the DHFR and TS domains.
Fig. 2. A representation of the crystal structure of L. major DHFR-TS prepared by Web-lab Viewer. The enzyme is a symmetrical dimer of TS and DHFR.
Fig. 3. Part of the active site of the L. major DHFR. This figure shows the
location of methotrexate and those residues in the active site of L. major
DHFR which are not homologous to the corresponding residues in human
DHFR (Glu43, Ser44, Met53, Lys57, Phe91).
Table 1
Sequence alignment (percentage identity) of DHFR from different
organisms
L. major T. cruzi T. brucei E. coli
Human 26 27 26 27
L. major 50 46 24
T. cruzi 58 26
T. brucei 23
Modified from Ref. [14] with permission.
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4. Inhibitors of parasite DHFR
4.1. Trimethoprim, cycloguanil, pyrimethamine and metho-
trexate: known DHFR inhibitors
Classical anti-microbial DHFR inhibitors, such as pyr-
imethamine and trimethoprim (Fig. 4) are, in general, not
very selective for the analogous leishmanial and trypanoso-
mal enzymes. Thus, trimethoprim (Ki = 0.12 AM), pyrimeth-
amine (Ki = 0.25 AM) and cycloguanil (Ki = 5.8 AM) are
only weakly active against L. major DHFR. Pyrimethamine
is weakly selective for the human, relative to the parasite
enzyme (1- to 2-fold). Trimethoprim has been reported as
weakly selective for either the L. major or human enzyme.
There is weak inhibition and selectivity of trimethoprim
(Ki = 1 AM, selectivity 1- to 30-fold) and pyrimethamine
(Ki = 0.1 AM, no selectivity) for the T. cruzi enzyme. In the
case of T. brucei, trimethoprim (Ki = 0.01 AM, selectivity
134- to 600-fold) and pyrimethamine (Ki = 0.01 AM, selec-
tivity 10-fold) were more selective for the parasite enzyme
[10,16–18].
Trimethoprim, pyrimethamine and cycloguanil are
weakly active against L. major promastigotes (EC50 = 175,
32, > 500 AM, respectively) and L. donovani amastigotes
(EC50 = 160, 34, >100 AM, respectively) [16,19]. In rodent
models of leishmaniasis, Peters et al. [20] reported that
activity was species-specific; trimethoprim exhibited some
activity against infection by L. major, cycloguanil had some
activity against infection by Leishmania infantum, while
pyrimethamine exhibited poor activity.
Methotrexate, a potent inhibitor of DHFR, is 8-fold
selective for the L. major DHFR, and also showed activity
against L. major promastigotes (EC50 = 0.3 AM) [12]. Scott
et al. [21] investigated the activity of methotrexate against
promastigotes from various species of Leishmania (L.
major, L. donovani, L. m. mexicana) and found L. major
most susceptible. Methotrexate has been reported as a potent
inhibitor of the T. cruzi enzyme (Ki = 0.038 nM), but it is
poorly active against the amastigotes (EC50 = 9.2 AM)
[18,22].
4.2. Novel DHFR inhibitors
Relatively little has been reported on the development of
specific inhibitors of leishmanial and trypanosome DHFR.
Coombs’ group [21,23] investigated some 5-substituted
2,4-diaminopyrimidines that were good inhibitors of L. m.
mexicana DHFR in crude extracts of the enzyme
(IC50 = 0.2–2 AM) and showed activity against the promas-
tigotes (EC50 = 12–24 AM) (Fig. 5). One of the compounds
was studied further in amastigotes, where it showed some
activity at concentrations below that at which it killed the
host macrophages. However, in a mouse study, the com-
pound was too toxic to warrant further study.
Quantitative structure activity relationship (QSAR) anal-
ysis was carried out on the inhibition of L. major [24] and
human [25] DHFR for a series of triazines of the general
structures shown in Fig. 6(a),(b). Compounds with lip-
ophilic substituents (X) showed greater activity than com-
pounds with polar substituents. However, few compounds
Fig. 4. Some clinically used DHFR inhibitors: pyrimethamine and cycloguanil as anti-malarials; trimethoprim as anti-bacterial; and methotrexate as anti-cancer.
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showed selectivity for the Leishmania enzyme over the
human enzyme, notable exceptions being when X = nonyl,
dodecyl and CH2O-1-napthyl. Some of the compounds were
assayed for activity against L. major promastigotes and
showed activities varying from 1 to 500 AM.
Sirawaraporn et al. [16] studied a series of substituted 5-
benzyl-2,4-diaminopyrimidines, some of which showed
selectivity for the L. major DHFR in enzyme assays and
moderate activity against L. major promastigotes and L.
donovani amastigotes. The most active and selective com-
pound in the enzyme assay experiments was the 8-octyloxy
derivative (n = 8, Fig. 6(c)), with a selectivity of 130-fold for
the L. major DHFR and EC50 against L. major promasti-
gotes of 5.6 AM and L. donovani amastigotes of 4.6 AM.
A detailed structure-activity study on these alkyl-substi-
tuted 5-benzyl-2,4-diaminopyrimidines (Fig. 6(c)) was
undertaken by Chowdhury et al. [17]. They varied the
length of the substituent chain from hydrogen to decyl
(n = 0 to n = 10) and also extended the study to include both
T. cruzi and T. brucei. Optimum activity and selectivity
against L. major, T. cruzi and T. brucei DHFR was found for
compounds with a chain length of 2–6 carbon atoms. The
maximum selectivities of these compounds, compared to the
human enzyme, were 20-, 5- and 250-fold, respectively, and
inhibition constants were 0.13, 0.22 and 0.01 AM, respec-
tively. These compounds were modelled in the active sites
of the L. major and human enzymes. In the L. major
enzyme, the alkyl chain of the substituent appears to interact
with a phenylalanine residue in the enzyme active site. This
interaction appears to be optimal for a chain length of 4–6
carbon atoms. As the alkyl chain length increases further,
the alkyl substituent appears to move away from the Phe
residue, decreasing the interaction and offering a possible
explanation for the optimal activity. This model can also
explain the selectivity of the compounds. In the human
enzyme, the phenylalanine is replaced by asparagine (Table
2) [14], which does not interact with the alkyl chain.
Table 2
Differences in residues in the folate binding sites of human and
trypanosomal and leishmanial DHFR
Human
Residue
L. major
residue
T. cruzi
residue
T. brucei
residue
Interaction with
folate
Gly20 Glu43 Arg39 Gly45 pteridine/NADPH
Asp21 Ser44 Ser40 Thr46 pteridine/NADPH
Phe31 Met53 Met49 Met55 pteridine/benzamidine/
glutamate
Gln35 Lys57 Arg53 Arg59 glutamate
Asn64 Phe91 Phe88 Phe94 glutamate
The portion of the substrate with which residues interact is indicated as
pteridine, benzamidine, and glutamate. Modified from Ref. [14] with
permission.
Fig. 5. A series of 2,4-diaminopyrimidines showing activity against Leishmania DHFR [21,23].
Fig. 6. Compounds (a) and (b) are the basic structures used for QSAR
analysis by Booth et al. [24] and Hathaway et al. [25]. Compound (c) is the
basic structure studied by Sirawaraporn et al. [16] and Chowdhury et al.
[17].
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Fig. 7. Examples of 2,4-diaminoquinazolines tested by Berman et al. [26]. The activities against the enzyme, L. major amastigotes cultured in macrophages and
cellular toxicity values (against macrophages) are given for the most active compounds.
Fig. 8. Quinazolines and 2,4-diaminopyrimidines showing activity against L. major DHFR [12].
Fig. 9. Differences in the active site between the human and T. cruzi enzymes used by Zuccotto et al. [22] to design novel inhibitors.
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These substituted 5-benzyl-2,4-diaminopyrimidines
showed in vitro activity against T. cruzi amastigotes and
T. brucei trypomastigotes, with the best activity being found
for chain lengths of 6–10 carbon atoms (Fig. 6(c)). The
most active compounds gave 100% inhibition of growth of
T. cruzi amastigotes at 3 AM and an EC50 of 1 AM against T.
brucei trypomastigotes. The chain length for optimum
activity against the intact parasites (6–10 carbon atoms)
does not correspond to that for optimum activity against the
enzyme (2–6 carbon atoms). This suggests that inhibition of
DHFR is not the only factor for activity against the parasite.
The compounds were generally inactive against L. infantum
amastigotes. In rodent models of African trypanosomiasis,
several of the 5-benzyl-2,4-diaminopyrimidines showed a
marginal effect, while against a rodent model of Chagas’
disease, the compounds were inactive.
Some 2,4-diaminoquinazolines investigated by Berman
et al. [26] showed reasonable inhibition of DHFR isolated
from L. mexicana promastigotes (Fig. 7). The compounds
also showed very potent activity against L. major amasti-
gotes cultured in human macrophages (ED50 = 0.04–25
nM), and a large therapeutic index compared to uninfected
macrophages. However, there was little correlation between
inhibition of DHFR and activity against the L. major
amastigotes, suggesting an alternate mode(s) of action, other
than or in addition to inhibition of DHFR, may be operating
with these compounds. In the case of T. cruzi, some 2,4-
diaminoquinazolines showed good activity against the
amastigote form [27,28] and were able to prolong the life
of infected mice, but not to give a radical cure [29].
Hardy et al. [12] screened a set of pteridines, quinazo-
lines and pyrimidines against L. major and human DHFR
and against L. major promastigotes (for representative
structures see Fig. 8). Generally, compounds that showed
good inhibition of DHFR were active against the L. major
promastigotes and conversely those which showed poor
activity against the DHFR were also poorly active against
the promastigotes. Some of the compounds also showed
reasonable levels of selectivity for the L. major enzyme over
the human enzyme; the most potent and selective com-
pounds were some quinazolines and a pyrimidine (Fig. 8).
However, some of these compounds were also active in L.
major promastigotes that lacked the enzyme DHFR-TS
suggesting that they might have (an) additional enzymatic
targets within the cell.
Zuccotto et al. [22] used differences in the structures of the
T. cruzi and human DHFRs to design a series of selective
inhibitors of the T. cruzi enzyme. In the human enzyme, the
channel linking the folate to the NADPH binding sites
contains the sequence Gly20–Asp21, which is overall neg-
atively charged. In contrast, the T. cruzi enzyme contains the
sequence Arg39–Ser40, which is overall positively charged
(Table 2). Modelling suggested substitution of a negatively
charged substituent on methotrexate should lead to repulsion
with Asp21 in the case of the human enzyme and possibly
attraction in the case of the T. cruzi enzyme (Fig. 9). The
compounds did appear to have increased selectivity for the
parasite enzyme but unfortunately showed weak in vitro
activity against T. cruzi amastigotes.
An approach to discover novel parasite DHFR inhibitors
using database mining has been reported by Chowdhury et
al. [30] and Zuccotto et al. [31] who used the programme
DOCK 3.5 [32] to search the Cambridge Structural Data-
base. The goal of their research was to find DHFR inhibitors
that were not based on the 2,4-diaminopyrimidine motif.
Chowdhury et al. [30] used the L. major active site for
docking and identified compounds with weak activity
against both the enzyme and parasite (EC50 = 20–60 AM).
Fig. 10. Examples of novel inhibitors of L. major (a) and T. cruzi (b) DHFR
identified by database mining using DOCK 3.5 [30,31].
Fig. 11. Reduction of biopterin by ptr1.
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It is not known whether this anti-parasitic activity is due to
inhibition of DHFR (Fig. 10(a)). Zuccotto et al. [31] found
one particular compound that had activity against T. cruzi
DHFR (Fig. 10(b)) and also showed good activity against T.
brucei trypomastigotes (EC50 = 3.6 AM).
5. Resistance
There are a number of possible mechanisms of resistance
to DHFR inhibitors in Leishmania which include over-
expression of the enzyme DHFR-TS and over-expression
of the enzyme ptr1.
ptr1 is an enzyme involved in the reduction of biopterin to
dihydrobiopterin and terahydrobiopterin (Fig. 11) [33,34]. It
has been shown that this enzyme can also reduce dihydrofo-
late to tetrahydrofolate, although the enzyme is structurally
unrelated to DHFR. Under normal conditions, the majority of
reduction of dihydrofolate to tetrahydrofolate is carried out
by DHFR. However, should ptr1 be over-expressed (which
has been demonstrated in laboratory models of resistance
[35]), then this enzyme could substitute, albeit much less
efficiently, for DHFR [36]. It has been shown that while it is
probable that ptr1 could not fully replace the role of DHFR, it
is important in reducing the sensitivity of Leishmania to
antifolates [37]. Compounds that inhibit both DHFR and ptr1
may make prospects as drug candidates [12]. While there are
differences in substrate specificity between DHFR and ptr1,
some compounds inhibit both well. The presence of ptr1 has
been shown in L. major promastigotes andmore recently in L.
mexicana amastigotes [38]. This contrasts to the situation in
T. cruzi where levels of ptr1 are not detectable in the
amastigote stage, although the enzyme is expressed in the
epimastigote (vector) form [39].
A recent publication by Beverley’s group [40] showed
that ptr1 knockouts are in fact more virulent against mouse
models of leishmaniasis than the wild-type, and they sug-
gest that targeting of ptr1 on its own is not a suitable drug
target.
6. Conclusions
DHFR is a drug target that has not been fully investigated
in the protozoan parasites Leishmania and Trypanosoma.
The structure of the enzyme and the enzyme specificity is
significantly different from that of the human enzyme
suggesting the possibility of selective drug design. How-
ever, clinical DHFR inhibitors in current use are not suitable
for treatment of the diseases caused by Leishmania and
Trypanosoma. Hence, there is need for development of new,
selective inhibitors, which are active in vivo. Several
potential mechanisms of resistance have been discovered,
including the enzyme ptr1. In order to avoid this mechanism
of resistance, it may be necessary to inhibit ptr1 in addition
to DHFR.
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